Algernon Pharmaceuticals Inc. (AGNPF)
USD 0.06
(10.5%)
USD 0.06
(10.5%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 5.01 Million CAD | -12.92% |
| 2022 | 6.01 Million CAD | -25.23% |
| 2021 | 8.05 Million CAD | -7.04% |
| 2020 | 8.66 Million CAD | 352.53% |
| 2019 | 1.91 Million CAD | 101.77% |
| 2018 | 948.55 Thousand CAD | -34.67% |
| 2017 | 1.45 Million CAD | -50.52% |
| 2016 | 2.93 Million CAD | 301.73% |
| 2015 | 730.46 Thousand CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 996.56 Thousand CAD | 90.92% |
| 2024 Q3 | 459.57 Thousand CAD | -53.27% |
| 2024 Q1 | 521.97 Thousand CAD | -47.05% |
| 2023 Q1 | 1.88 Million CAD | -15.21% |
| 2023 Q4 | 985.84 Thousand CAD | -12.6% |
| 2023 FY | 5.24 Million CAD | -12.92% |
| 2023 Q3 | 1.12 Million CAD | -9.6% |
| 2023 Q2 | 1.24 Million CAD | -33.64% |
| 2022 Q1 | 1.2 Million CAD | 119.95% |
| 2022 Q4 | 2.21 Million CAD | 176.8% |
| 2022 Q3 | 801.16 Thousand CAD | -56.38% |
| 2022 Q2 | 1.83 Million CAD | 52.92% |
| 2022 FY | 6.01 Million CAD | -25.23% |
| 2021 Q4 | 546.03 Thousand CAD | -67.43% |
| 2021 Q3 | 1.67 Million CAD | -29.81% |
| 2021 FY | 8.05 Million CAD | -7.04% |
| 2021 Q2 | 2.38 Million CAD | -30.59% |
| 2021 Q1 | 3.44 Million CAD | 20.36% |
| 2020 Q2 | 793.77 Thousand CAD | 208.6% |
| 2020 FY | 8.66 Million CAD | 352.53% |
| 2020 Q3 | 4.6 Million CAD | 480.11% |
| 2020 Q4 | 2.85 Million CAD | -37.92% |
| 2020 Q1 | 257.21 Thousand CAD | -39.58% |
| 2019 Q4 | 425.69 Thousand CAD | -20.1% |
| 2019 Q2 | 446.99 Thousand CAD | -12.09% |
| 2019 Q1 | 508.46 Thousand CAD | 162.14% |
| 2019 FY | 1.91 Million CAD | 101.77% |
| 2019 Q3 | 532.76 Thousand CAD | 19.19% |
| 2018 Q1 | 196.25 Thousand CAD | -33.29% |
| 2018 FY | 948.55 Thousand CAD | -34.67% |
| 2018 Q4 | 193.96 Thousand CAD | -51.2% |
| 2018 Q3 | 397.46 Thousand CAD | 147.08% |
| 2018 Q2 | 160.86 Thousand CAD | -18.04% |
| 2017 Q3 | 323.6 Thousand CAD | -0.64% |
| 2017 FY | 1.45 Million CAD | -50.52% |
| 2017 Q4 | 294.21 Thousand CAD | -9.08% |
| 2017 Q1 | 508.46 Thousand CAD | 83.39% |
| 2017 Q2 | 325.68 Thousand CAD | -35.95% |
| 2016 Q1 | 160.64 Thousand CAD | -69.5% |
| 2016 Q4 | 277.25 Thousand CAD | -41.32% |
| 2016 Q3 | 472.51 Thousand CAD | -76.65% |
| 2016 Q2 | 2.02 Million CAD | 1159.46% |
| 2016 FY | 2.93 Million CAD | 301.73% |
| 2015 Q3 | 203.79 Thousand CAD | 0.0% |
| 2015 Q4 | 526.67 Thousand CAD | 158.44% |
| 2015 FY | 730.46 Thousand CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| ContraFect Corporation | 56.88 Million USD | 91.179% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -28704.632% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 20172.22% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -274.05% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 94.218% |
| Kadimastem Ltd | 2.41 Million USD | -108.208% |
| Zenith Capital Corp. | 8.94 Million USD | 43.888% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -169.156% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -19837.443% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 25.304% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -1817.293% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -239.344% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 86.531% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -234.114% |
| Qrons Inc. | 643.67 Thousand USD | -679.592% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -217.728% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -104.375% |
| Accustem Sciences Inc. | 3.74 Million USD | -33.943% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -843.311% |
| Affymax, Inc. | 39.38 Million USD | 87.259% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 94.948% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 0.476% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -79.836% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -275.763% |
| Biomind Labs Inc. | 994.18 Thousand USD | -404.742% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 53.823% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -90.981% |
| CytoDyn Inc. | 18.05 Million USD | 72.211% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 83.02% |
| IMV Inc. | 37.7 Million USD | 86.693% |
| Genus plc | 147.7 Million USD | 96.603% |
| Halberd Corporation | 74.84 Thousand USD | -6604.865% |
| Helix BioMedix, Inc. | 1.97 Million USD | -154.461% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -2.036% |
| LadRx Corporation | 3.81 Million USD | -31.646% |
| Marizyme, Inc. | 19.23 Million USD | 73.918% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -2180.126% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 79.696% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -13.822% |
| Q BioMed Inc. | 3.43 Million USD | -46.017% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -443.368% |
| Enzolytics Inc. | 2.17 Million USD | -130.238% |
| CSL Limited | 3.44 Billion USD | 99.855% |
| Skye Bioscience, Inc. | 13.54 Million USD | 62.96% |
| SQZ Biotechnologies Company | 85.61 Million USD | 94.139% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -144.938% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 42.842% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -2825.826% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -108.657% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -380.657% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 39.824% |
| NovAccess Global Inc. | 2.46 Million USD | -103.427% |
| HST Global, Inc. | 140.9 Thousand USD | -3461.253% |
| SYBLEU INC | 160.87 Thousand USD | -3019.207% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 94.161% |
| Alpha Cognition Inc. | 9.7 Million USD | 48.297% |
| AVAX Technologies, Inc. | 7.31 Million USD | 31.356% |
| Mesoblast Limited | 5.9 Million USD | 14.977% |
| MultiCell Technologies, Inc. | 567.42 USD | -884263.434% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -72.073% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 68.657% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -1188.114% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 225.49 Million USD | 97.775% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -173.449% |
| GB Sciences, Inc. | 1.42 Million USD | -253.258% |
| argenx SE | 1.53 Billion USD | 99.673% |
| Resverlogix Corp. | 12.71 Million USD | 60.525% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -37.454% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 91.264% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -185.169% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -47.374% |
| ONE Bio Corp. | 6.44 Million USD | 22.127% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.392% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -161.234% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -346.085% |
| Agentix Corp. | 1.37 Million USD | -265.813% |
| Adynxx, Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 22.97 Million USD | 78.158% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -2664.997% |
| Cell Source, Inc. | 4.32 Million USD | -16.015% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -1107.776% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -443.368% |
| Itoco Inc. | 919.14 Thousand USD | -445.949% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -18.395% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -348.441% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -253.436% |
| Nascent Biotech, Inc. | 2.22 Million USD | -125.037% |
| Rebus Holdings, Inc. | 664 Thousand USD | -655.731% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -176.276% |
| Mobile Lads Corp. | 554.54 Thousand USD | -804.894% |
| International Stem Cell Corporation | 5.27 Million USD | 4.799% |
| Bioxytran, Inc. | 3.82 Million USD | -31.358% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -9432.417% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -24567.232% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 86.163% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -210.139% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -581.954% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -61.3% |
| Neutra Corp. | 243.82 Thousand USD | -1958.09% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 71.255% |
| PureTech Health plc | 144.59 Million USD | 96.53% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 75.51% |
| IXICO plc | 4.7 Million USD | -6.608% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 42.957% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 95.738% |
| CSL Limited | 3.89 Billion USD | 99.871% |
| Cellectis S.A. | 97.32 Million USD | 94.844% |